<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700072</url>
  </required_header>
  <id_info>
    <org_study_id>3475-02D</org_study_id>
    <secondary_id>2020-003742-36</secondary_id>
    <secondary_id>MK-3475-02D</secondary_id>
    <secondary_id>KEYMAKER-U02</secondary_id>
    <nct_id>NCT04700072</nct_id>
  </id_info>
  <brief_title>Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)</brief_title>
  <official_title>A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Substudy 02D is part of a larger research study that is testing experimental treatments for&#xD;
      melanoma, a type of skin cancer. The larger study is the umbrella study.&#xD;
&#xD;
      The goal of substudy 02D is to evaluate the safety and efficacy of investigational treatment&#xD;
      arms in programmed cell-death 1 (PD-1) naïve or PD-1 exposed participants with melanoma brain&#xD;
      metastasis (MBM) and to identify the investigational agent(s) that, when used in combination,&#xD;
      are superior to the current treatment options/historical control available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">April 3, 2030</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2030</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants who experience an adverse event (AE)</measure>
    <time_frame>Up to ~28 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants who discontinue study treatment due to an AE</measure>
    <time_frame>Up to ~24 months</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per RECIST 1.1</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>For participants in the analysis population who demonstrate a confirmed CR (disappearance of all target lesions) or confirmed PR (≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR is defined as the time from first documented CR or PR until progressive disease (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of ≥1 new lesion is also considered PD. Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain metastasis response rate (BMRR) per Response Assessment in Neuro- Oncology Brain Metastases (RANO-BM)</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>BMRR is defined as the percentage of participants in the analysis population who achieve a confirmed intracranial CR (disappearance of all lesions, no usage of corticosteroids and stable or improved clinical status) or PR (≥30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters, no progression of non-target lesions or new lesions, stable or decreased corticosteroid use, or stable or improved clinical status). Responses are according to RANO-BM as assessed by BICR. RANO-BM uses a combination of RECIST 1.1 and clinical data to assess response to treatment in brain metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain metastasis duration of response (BM-DOR) per RANO-BM</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>For participants in the analysis population who demonstrate a confirmed intracranial CR (disappearance of all lesions, no usage of corticosteroids, stable or improved clinical status) or PR (≥30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters, no progression of non-target lesions or new lesions, stable or decreased corticosteroid use, or stable or improved clinical status), DOR is defined as the time from first documented CR or PR until PD or death due to any cause, whichever occurs first. Per RANO-BM, PD is defined as ≥20% increase in the sum of diameters of target lesions and an absolute increase of ≥5 mm in ≥1 lesion. Unequivocal increase in non-target lesions, the appearance of ≥1 new lesion or worsening of clinical status is also considered PD. Responses are according to RANO-BM as assessed by BICR. RANO-BM uses a combination of RECIST 1.1 and clinical data to assess response to treatment in brain metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per RECIST 1.1</measure>
    <time_frame>Up to ~30 months</time_frame>
    <description>PFS is defined as the time from randomization to the first documented PD or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Coformulation Pembrolizumab/Quavonlimab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab/quavonlimab (coformulation of pembrolizumab and quavonlimab) intravenously (IV) plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive pembrolizumab IV plus lenvatinib orally at specified doses on specified days for a total treatment duration of up to approximately 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered via IV infusion at a specified dose on specified days</description>
    <arm_group_label>Coformulation Pembrolizumab/Quavonlimab + Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <other_name>MK-3475</other_name>
    <other_name>KEYTRUDA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab/Quavonlimab</intervention_name>
    <description>Administered via IV infusion at a specified dose on specified days</description>
    <arm_group_label>Coformulation Pembrolizumab/Quavonlimab + Lenvatinib</arm_group_label>
    <other_name>MK-1308A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenvatinib</intervention_name>
    <description>Administered via oral capsule at a specified dose on specified days</description>
    <arm_group_label>Coformulation Pembrolizumab/Quavonlimab + Lenvatinib</arm_group_label>
    <arm_group_label>Pembrolizumab + Lenvatinib</arm_group_label>
    <other_name>MK-7902</other_name>
    <other_name>E7080</other_name>
    <other_name>LENVIMA®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has American Joint Committee on Cancer (AJCC) Stage IV, M1D melanoma&#xD;
&#xD;
          -  Is neurologically asymptomatic from brain metastases and has not received systemic&#xD;
             corticosteroid therapy in the 10 days prior to beginning study intervention&#xD;
&#xD;
          -  Has not received more than 3 lines of therapy for metastatic melanoma&#xD;
&#xD;
          -  Male participants are abstinent from heterosexual intercourse or agree to use&#xD;
             contraception during the intervention period&#xD;
&#xD;
          -  Female participants are not pregnant or breastfeeding and are either not a woman of&#xD;
             child-bearing potential (WOCBP) OR use a contraceptive method that is highly effective&#xD;
             or are abstinent from heterosexual intercourse during the intervention period and for&#xD;
             at least 120 days after the last dose of pembrolizumab or pembrolizumab/quavonlimab,&#xD;
             or 30 days after the last dose of lenvatinib, whichever occurs last&#xD;
&#xD;
          -  Has adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within&#xD;
             10 days before the first dose of study intervention&#xD;
&#xD;
          -  Has current or history of known leptomeningeal involvement&#xD;
&#xD;
          -  Has received stereotactic or highly conformal radiotherapy within 2 weeks before the&#xD;
             start of dosing&#xD;
&#xD;
          -  Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the&#xD;
             first dose of study drug&#xD;
&#xD;
          -  Has untreated or unresolved intracranial hemorrhage from central nervous system (CNS)&#xD;
             metastasis&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy&#xD;
&#xD;
          -  Has a known additional malignancy that is progressing or requires active treatment&#xD;
             within the past 2 years&#xD;
&#xD;
          -  Has ocular melanoma&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in the past 2&#xD;
             years&#xD;
&#xD;
          -  Has known history of immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Has known history of hepatitis B or known hepatitis C virus&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis that required steroids or current&#xD;
             pneumonitis&#xD;
&#xD;
          -  Has received prior systemic anticancer therapy within 4 weeks prior to&#xD;
             randomization/allocation&#xD;
&#xD;
          -  Has a history of whole brain irradiation&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of first dose of study intervention&#xD;
&#xD;
          -  Has had major surgery &lt;3 weeks prior to first dose of study intervention&#xD;
&#xD;
          -  Has received a live or live attenuated vaccine within 30 days prior to the first dose&#xD;
             of study intervention&#xD;
&#xD;
          -  Has had an allogeneic tissue/solid organ transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic and Research Institute ( Site 4009)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology ( Site 4004)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-794-6892</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Saint John's Health Center ( Site 4010)</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>310-582-7455</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Cancer Pavilion ( Site 4012)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-848-0442</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 4022)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NYU Clinical Cancer Center ( Site 4002)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>999-999-9999</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute ( Site 4005)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>919-660-9671</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute ( Site 4011)</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>571-472-0631</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Melanoma Institute Australia ( Site 4402)</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61299117321</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Calvary Mater Newcastle ( Site 4404)</name>
      <address>
        <city>Waratah</city>
        <state>New South Wales</state>
        <zip>2298</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+61240143287</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone ( Site 4103)</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du-Rhone</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33491388591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud ( Site 4105)</name>
      <address>
        <city>Toulouse cedex 9</city>
        <state>Haute-Garonne</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33531155101</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud ( Site 4102)</name>
      <address>
        <city>Pierre Benite</city>
        <state>Rhone</state>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+33478861628</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HaEmek Medical Center ( Site 4703)</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97246495723</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus-Oncology ( Site 4704)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97247776700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Jerusalem ( Site 4702)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97226776781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center ( Site 4701)</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+97235304907</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 4399)</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390223902557</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia ( Site 4301)</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390105600384</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale ( Site 4302)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+390815903431</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Le Scotte - A.O. Senese ( Site 4377)</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>00390577586335</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHUV Centre Hospitalier Universitaire Vaudois ( Site 4602)</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41213140155</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Zuerich ( Site 4601)</name>
      <address>
        <city>Zurich</city>
        <zip>8058</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+41442552588</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 5, 2021</study_first_submitted>
  <study_first_submitted_qc>January 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>programmed cell death 1 (PD-1, PD1)</keyword>
  <keyword>programmed cell death ligand 1 (PD-L1, PDL1)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

